-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Critical Survey: Better Therapeutics (BTTX) Versus Its Rivals
Critical Survey: Better Therapeutics (BTTX) Versus Its Rivals
Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 publicly-traded companies in the "Health services" industry, but how does it compare to its rivals? We will compare Better Therapeutics to related businesses based on the strength of its valuation, institutional ownership, profitability, risk, dividends, analyst recommendations and earnings.
Institutional and Insider Ownership
7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 21.6% of shares of all "Health services" companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Get Better Therapeutics alerts:Valuation and Earnings
This table compares Better Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.74 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 36.86 |
Analyst Ratings
This is a summary of recent ratings and target prices for Better Therapeutics and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 277 | 0 | 2.65 |
Better Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 839.60%. As a group, "Health services" companies have a potential upside of 89.14%. Given Better Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Better Therapeutics is more favorable than its rivals.
Volatility & Risk
Better Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' rivals have a beta of 1.19, indicating that their average share price is 19% more volatile than the S&P 500.
Profitability
This table compares Better Therapeutics and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
Summary
Better Therapeutics beats its rivals on 8 of the 12 factors compared.
About Better Therapeutics
(Get Rating)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 publicly-traded companies in the "Health services" industry, but how does it compare to its rivals? We will compare Better Therapeutics to related businesses based on the strength of its valuation, institutional ownership, profitability, risk, dividends, analyst recommendations and earnings.
Better Treateutics(納斯達克代碼：BTTX-GET Rating)是“健康服務”行業的33家上市公司之一，但與其競爭對手相比如何？我們將根據其估值、機構所有權、盈利能力、風險、股息、分析師建議和收益的實力，將Better Treateutics與相關業務進行比較。
Institutional and Insider Ownership
機構和內部人持股
7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 21.6% of shares of all "Health services" companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Better Treateutics 7.5%的股份由機構投資者持有。相比之下，所有“健康服務”公司48.6%的股份由機構投資者持有。Better Treateutics 59.4%的股份由公司內部人士持有。相比之下，所有“健康服務”公司21.6%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一家公司的長期表現將好於大盤。
Valuation and Earnings
估值和收益
This table compares Better Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
此表比較了Better Treateutics及其競爭對手的營收、每股收益(EPS)和估值。
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.74 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 36.86 |
| 總收入 | 淨收入 | 市盈率 | |
| 更好的治療學 | $10,000.00 | -4,033萬元 | -0.74 |
| Better Treateutics的競爭對手 | 13.6億美元 | -9,847萬元 | 36.86 |
Analyst Ratings
分析師評級
This is a summary of recent ratings and target prices for Better Therapeutics and its rivals, as provided by MarketBeat.
這是由MarketBeat提供的Better Treateutics及其競爭對手最近的評級和目標價格摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 277 | 0 | 2.65 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 更好的治療學 | 0 | 0 | 2 | 0 | 3.00 |
| Better Treateutics的競爭對手 | 7 | 131 | 277 | 0 | 2.65 |
Better Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 839.60%. As a group, "Health services" companies have a potential upside of 89.14%. Given Better Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Better Therapeutics is more favorable than its rivals.
Better Treateutics目前的共識目標價為14.00美元，這意味着潛在的上漲839.60%。作為一個整體，“健康服務”公司有89.14%的潛在上行空間。鑑於Better Treeutics更高的共識評級和更高的可能上行空間，研究分析師顯然認為Better Treateutics比其競爭對手更有利。
Volatility & Risk
波動性與風險
Better Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' rivals have a beta of 1.19, indicating that their average share price is 19% more volatile than the S&P 500.
Better Treateutics的貝塔係數為1.36，這表明其股價的波動性比標準普爾500指數高36%。相比之下，Better Treateutics的競爭對手的貝塔係數為1.19，這表明它們的平均股價波動性比標準普爾500指數高19%。
Profitability
盈利能力
This table compares Better Therapeutics and its rivals' net margins, return on equity and return on assets.
下表比較了Better Treeutics及其競爭對手的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 更好的治療學 | 不適用 | -200.73% | -114.68% |
| Better Treateutics的競爭對手 | -325.87% | -676.77% | -37.31% |
Summary
摘要
Better Therapeutics beats its rivals on 8 of the 12 factors compared.
Better Treateutics在比較的12個因素中有8個擊敗了競爭對手。
About Better Therapeutics
關於Better Treatetics
(Get Rating)
(獲取評級)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Better Treateutics，Inc.，一家處方數字治療公司，開發了一種認知行為療法，以解決心臟代謝性疾病的原因。該公司開發基於軟件的處方數字療法平臺，用於治療糖尿病、心臟病和其他心臟代謝疾病。其臨牀開發候選藥物旨在治療心臟代謝性疾病，包括2型糖尿病、高血壓、高脂血症、非酒精性脂肪性肝病、非酒精性脂肪性肝炎和慢性腎臟疾病。該公司的主要候選產品是BT-001，這是一種治療2型糖尿病的研究PDT平臺。Better Treateutics，Inc.成立於2015年，總部位於加利福尼亞州舊金山。
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到更好的治療新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對Better Treateutics和相關公司的評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧